Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea ...

Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

STRATA management will host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management’s formal ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: ...

Alumis received an upfront license fee of $20.0 million in March 2025 and will receive an additional $20.0 million in near-term co-development payments, with potential for additional milestone ...

SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life ...

Nasdaq BioCardia Reports First Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and ...

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC. Topline data from DENALI Part 2 anticipated by year end 2026 with the potenti ...

In March 2025, the European Patent Office issued a Notice of Allowance for a new patent application (European Patent Appl. No. 20798130.9) covering key aspects of BioRestorative’s allogeneic, ...

Codexis reiterated its full-year 2025 financial guidance originally issued on February 27, 2025, as follows: Total revenues are expected to be in the range of $64 million to $68 million.

Clearside’s Asia-Pacific collaboration partner, Arctic Vision, announced that its New Drug Application (NDA) for ARCATUS ® (known as XIPERE ® in the U.S.) was formally accepted for review by the ...

Cash position: Tenax Therapeutics reported cash and cash equivalents of $111.4 million as of March 31, 2025. In March 2025, the Company raised approximately $25 million in gross proceeds from a ...